Sanofi: Number of Employees 2010-2023 | SNY

Interactive chart of Sanofi (SNY) annual worldwide employee count from 2010 to 2023.
  • Sanofi total number of employees in 2023 was 86,088, a 5.99% decline from 2022.
  • Sanofi total number of employees in 2022 was 91,573, a 4.05% decline from 2021.
  • Sanofi total number of employees in 2021 was 95,442, a 3.99% decline from 2020.
  • Sanofi total number of employees in 2020 was 99,412, a 0.99% decline from 2019.
Sanofi Annual Employee Count
2023 86,088
2022 91,573
2021 95,442
2020 99,412
2019 100,409
2018 104,226
2017 106,566
2016 106,859
2015 115,631
2014 113,496
2013 112,128
2012 111,974
2011 113,719
2010 101,575
2009 104,867
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $117.121B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Novo Nordisk (NVO) Denmark $550.665B 45.36
Johnson & Johnson (JNJ) United States $356.431B 14.14
Merck (MRK) United States $318.604B 83.85
AbbVie (ABBV) United States $294.653B 14.98
AstraZeneca (AZN) United Kingdom $212.533B 18.83
Novartis AG (NVS) Switzerland $200.005B 13.86
Pfizer (PFE) United States $147.226B 14.21
Innoviva (INVA) United States $0.945B 6.67